Natural history of benign prostatic hyperplasia

被引:131
作者
Jacobsen, SJ
Girman, CJ
Lieber, MM
机构
[1] Mayo Clin, Dept Hlth Sci Res, Clin Epidemiol Sect, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Urol, Rochester, MN 55905 USA
[3] Merck Res Labs, Blue Bell, PA USA
关键词
D O I
10.1016/S0090-4295(01)01298-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Studies in varied settings have provided estimates of the prevalence of surrogate markers of benign prostatic hyperplasia (BPH). In population-based studies, the prevalence of moderate-to-severe lower urinary tract symptoms and depressed peak urinary flow rates increases across successively older age groups. Prostatic volume follows a similar pattern. Unlike clinic-based studies in which correlations are almost nonexistent, the population-based studies demonstrate a modest correlation among lower urinary tract symptoms, peak urinary flow rates, and prostatic volume. These cross-sectional observations extend to serum prostate-specific antigen levels and postvoid residual urine volumes. Data collected during the longitudinal follow-up study of men participating in the Olmsted County Study of Urinary Symptoms and Health Status Among Men provide a more detailed description of the natural history of changes in these surrogate markers of BPH. They also provide insights into their relation with each other and with long-term outcomes of BPH, such as acute urinary retention and treatment of BPH. These data demonstrate the progressive nature of BPH and are useful for the design and interpretation of clinical trials. Furthermore, they suggest that observational studies of etiology and prognosis should take advantage of the spectrum of disease reflected by the full range of values of these quantitative traits, rather than an arbitrary dichotomized outcome. (C) 2001, Elsevier Science Inc.
引用
收藏
页码:5 / 16
页数:12
相关论文
共 89 条
[61]   BPSA, a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia [J].
Mikolajczyk, SD ;
Millar, LS ;
Wang, TJ ;
Rittenhouse, HG ;
Wolfert, RL ;
Marks, LS ;
Song, WT ;
Wheeler, TM ;
Slawin, KM .
UROLOGY, 2000, 55 (01) :41-45
[62]   Age-specific reference ranges for serum prostate-specific antigen in black men [J].
Morgan, TO ;
Jacobsen, SJ ;
McCarthy, WF ;
Jacobson, DJ ;
McLeod, DG ;
Moul, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (05) :304-310
[63]   SERUM PROSTATE-SPECIFIC ANTIGEN IN A COMMUNITY-BASED POPULATION OF HEALTHY JAPANESE MEN - LOWER VALUES THAN FOR SIMILARLY AGED WHITE MEN [J].
OESTERLING, JE ;
KUMAMOTO, Y ;
TSUKAMOTO, T ;
GIRMAN, CJ ;
GUESS, HA ;
MASUMORI, N ;
JACOBSEN, SJ ;
LIEBER, MM .
BRITISH JOURNAL OF UROLOGY, 1995, 75 (03) :347-353
[64]   SERUM PROSTATE-SPECIFIC ANTIGEN IN A COMMUNITY-BASED POPULATION OF HEALTHY-MEN - ESTABLISHMENT OF AGE-SPECIFIC REFERENCE RANGES [J].
OESTERLING, JE ;
JACOBSEN, SJ ;
CHUTE, CG ;
GUESS, HA ;
GIRMAN, CJ ;
PANSER, LA ;
LIEBER, MM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (07) :860-864
[65]   PROSTATE SPECIFIC ANTIGEN - A CRITICAL-ASSESSMENT OF THE MOST USEFUL TUMOR-MARKER FOR ADENOCARCINOMA OF THE PROSTATE [J].
OESTERLING, JE .
JOURNAL OF UROLOGY, 1991, 145 (05) :907-923
[66]  
PAPSIDERO LD, 1981, J NATL CANCER I, V66, P37
[67]   Longitudinal analysis of serial measurements of free and total psa among men with and without prostatic cancer [J].
Pearson, JD ;
Luderer, AA ;
Metter, EJ ;
Partin, AW ;
Chan, DW ;
Fozard, JL ;
Carter, HB .
UROLOGY, 1996, 48 (6A) :4-9
[68]   ACCURACY OF INVIVO ASSESSMENT OF PROSTATIC VOLUME BY MRI AND TRANSRECTAL ULTRASONOGRAPHY [J].
RAHMOUNI, A ;
YANG, A ;
TEMPANY, CMC ;
FRENKEL, T ;
EPSTEIN, J ;
WALSH, P ;
LEICHNER, PK ;
RICCI, C ;
ZERHOUNI, E .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1992, 16 (06) :935-940
[69]   Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old - Comment [J].
Chancellor, MB .
JOURNAL OF UROLOGY, 1999, 161 (04) :1179-1179
[70]  
Roberts RO, 1999, AM J EPIDEMIOL, V150, P321